Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous cytokine-induced killer cells (Italian Sarcoma Group)
- Development stage
- Unknown
- Lead developer
- Italian Sarcoma Group
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Autologous cytokine-induced killer (CIK) cells are an adoptive immunotherapy consisting of ex vivo expanded T lymphocytes that express both T-cell (CD3+) and natural killer (NK) cell (CD56+) markers. Developed by the Italian Sarcoma Group for the treatment of advanced, relapsed, and non-resectable sarcomas, these cells exhibit potent, MHC-independent antitumor activity. This cytotoxicity is primarily mediated by the NKG2D receptor, which recognizes stress-induced ligands on tumor cells. The production process involves collecting a patient's peripheral blood, expanding the CIK population in a specialized cell factory (such as the Regina Margherita Children's Hospital Cell Factory), and re-infusing the cells into the patient.
- Other names
- autologous CIK cellsCIK cellsautologous cytokine-induced killer cellsautologous CIK-Italian Sarcoma Group-sarcoma
Beyond the preview
Go deeper on autologous cytokine-induced killer cells (Italian Sarcoma Group).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous cytokine-induced killer cells (Italian Sarcoma Group).